RS58322B1 - Samidorfan (alks 33) u kombinaciji sa buprenorfinom za lečenje depresivnih poremećaja - Google Patents

Samidorfan (alks 33) u kombinaciji sa buprenorfinom za lečenje depresivnih poremećaja

Info

Publication number
RS58322B1
RS58322B1 RS20181543A RSP20181543A RS58322B1 RS 58322 B1 RS58322 B1 RS 58322B1 RS 20181543 A RS20181543 A RS 20181543A RS P20181543 A RSP20181543 A RS P20181543A RS 58322 B1 RS58322 B1 RS 58322B1
Authority
RS
Serbia
Prior art keywords
samidorphan
alks
buprenorphine
treatment
combination
Prior art date
Application number
RS20181543A
Other languages
English (en)
Inventor
Daniel Deaver
Elliott Ehrich
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of RS58322B1 publication Critical patent/RS58322B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20181543A 2011-12-15 2012-12-14 Samidorfan (alks 33) u kombinaciji sa buprenorfinom za lečenje depresivnih poremećaja RS58322B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576233P 2011-12-15 2011-12-15
EP16201359.3A EP3153171B1 (en) 2011-12-15 2012-12-14 Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders

Publications (1)

Publication Number Publication Date
RS58322B1 true RS58322B1 (sr) 2019-03-29

Family

ID=47757653

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181543A RS58322B1 (sr) 2011-12-15 2012-12-14 Samidorfan (alks 33) u kombinaciji sa buprenorfinom za lečenje depresivnih poremećaja

Country Status (24)

Country Link
US (8) US8822488B2 (sr)
EP (3) EP2790702B1 (sr)
JP (2) JP6038170B2 (sr)
KR (1) KR101996108B1 (sr)
CN (2) CN106727562B (sr)
AU (1) AU2012351806C1 (sr)
BR (1) BR112014012409B8 (sr)
CA (1) CA2858812C (sr)
CY (1) CY1121081T1 (sr)
DK (1) DK3153171T3 (sr)
EA (1) EA030609B8 (sr)
ES (2) ES2692771T3 (sr)
HR (1) HRP20181950T1 (sr)
HU (1) HUE041883T2 (sr)
IL (1) IL232785B (sr)
LT (1) LT3153171T (sr)
MX (1) MX2014007042A (sr)
PL (1) PL3153171T3 (sr)
PT (1) PT3153171T (sr)
RS (1) RS58322B1 (sr)
SI (1) SI3153171T1 (sr)
TR (1) TR201815154T4 (sr)
WO (1) WO2013088243A1 (sr)
ZA (1) ZA201405029B (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EA030609B8 (ru) 2011-12-15 2018-10-31 Алкермес Фарма Айэленд Лимитед Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
EP3004114B1 (en) 2013-05-24 2019-12-25 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為hdac抑制劑之雙環[4,6,0]異羥肟酸
EA201792673A1 (ru) 2015-02-02 2018-04-30 Форма Терапьютикс, Инк. 3-арил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (sr) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
AR005423A1 (es) 1996-01-10 1999-06-23 Smithkline Beecham Spa Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
EP1353909B1 (en) 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
JP2005528359A (ja) * 2002-03-20 2005-09-22 ユーロ−セルティーク エス.エイ. うつ病の治療のためのブプレノルフィンの投与方法
DE60302157T2 (de) 2002-05-30 2006-07-27 Eli Lilly And Co., Indianapolis Opioidrezeptorantagonisten
CA2566601C (en) 2004-05-14 2013-04-09 Janssen Pharmaceutica N.V. Carboxamido opioid compounds
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
RU2415131C2 (ru) 2004-11-05 2011-03-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
US20090053329A1 (en) 2007-03-19 2009-02-26 Acadia Pharmaceuticals, Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN101827819B (zh) 2007-08-09 2013-06-12 伦斯勒理工学院 阿片样物质酰胺季铵盐
JP2011512360A (ja) * 2008-02-14 2011-04-21 アルカーメス,インコーポレイテッド 選択的オピオイド化合物
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
HUE043963T2 (hu) * 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
EA030609B8 (ru) * 2011-12-15 2018-10-31 Алкермес Фарма Айэленд Лимитед Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3003311A2 (en) * 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms

Also Published As

Publication number Publication date
EP3153171B1 (en) 2018-09-19
ES2692771T3 (es) 2018-12-05
AU2012351806B2 (en) 2016-03-10
EP3415148A1 (en) 2018-12-19
WO2013088243A1 (en) 2013-06-20
US20180078543A1 (en) 2018-03-22
EA030609B1 (ru) 2018-08-31
US8822488B2 (en) 2014-09-02
US10188643B2 (en) 2019-01-29
PL3153171T3 (pl) 2019-02-28
CN106727562B (zh) 2019-07-05
US20210196703A1 (en) 2021-07-01
PT3153171T (pt) 2018-11-16
IL232785B (en) 2021-04-29
ZA201405029B (en) 2015-10-28
US20180078542A1 (en) 2018-03-22
CA2858812A1 (en) 2013-06-20
JP6403726B2 (ja) 2018-10-10
BR112014012409A2 (pt) 2017-06-13
US10314838B2 (en) 2019-06-11
EA030609B8 (ru) 2018-10-31
JP2016222706A (ja) 2016-12-28
EA201491153A1 (ru) 2015-04-30
DK3153171T3 (en) 2018-11-19
TR201815154T4 (tr) 2018-11-21
AU2012351806A1 (en) 2014-05-15
CY1121081T1 (el) 2019-12-11
JP2015505853A (ja) 2015-02-26
BR112014012409B1 (pt) 2022-08-23
HRP20181950T1 (hr) 2019-03-22
KR20140107258A (ko) 2014-09-04
LT3153171T (lt) 2018-12-10
EP2790702A1 (en) 2014-10-22
US20170056392A1 (en) 2017-03-02
US10806731B2 (en) 2020-10-20
NZ624056A (en) 2016-07-29
US20160256450A1 (en) 2016-09-08
JP6038170B2 (ja) 2016-12-07
US20190247387A1 (en) 2019-08-15
KR101996108B1 (ko) 2019-10-01
US20130190342A1 (en) 2013-07-25
HUE041883T2 (hu) 2019-06-28
EP2790702B1 (en) 2020-04-01
IL232785A0 (en) 2014-07-31
US9918978B2 (en) 2018-03-20
CN104159586A (zh) 2014-11-19
ES2791764T3 (es) 2020-11-05
CN106727562A (zh) 2017-05-31
US9498474B2 (en) 2016-11-22
AU2012351806C1 (en) 2016-06-16
US9913837B2 (en) 2018-03-13
SI3153171T1 (sl) 2019-01-31
US20150051240A1 (en) 2015-02-19
EP3153171A1 (en) 2017-04-12
BR112014012409B8 (pt) 2022-09-13
CA2858812C (en) 2019-02-26
MX2014007042A (es) 2015-01-22

Similar Documents

Publication Publication Date Title
HRP20181950T1 (hr) Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
IL260585B (en) Preparations and methods for the treatment of diseases related to the retina of the eye
EP2684167A4 (en) COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
EP2552433A4 (en) COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201304334B (en) Methods for diagnosing and treating eye-length related disorders
ME02180B (me) Supstanca korisna za lečenje poremećaja metabolizma lipida
IL228030A0 (en) Methods and compositions for the treatment of gout and gout-related metabolic disorders
EP2696874A4 (en) COMPOSITIONS AND METHODS USED TO TREAT NASAL CONDITIONS
HK1194665A1 (zh) 用於治療神經系統病症的組合物
EP2691529A4 (en) METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
IL231593B (en) Buprenorphine for the treatment of acute suicidality
EP2675275A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
EP2681209A4 (en) COMPOUNDS AND METHODS FOR TREATING PAIN AND OTHER DISEASES
EP2723339A4 (en) COMPOUNDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES AND OTHER NEURODEGENERATIVE DISEASES
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
HK1257401A1 (zh) 用於治療糖尿病和相關病症的方法和組合物
EP2744502A4 (en) METHODS USEFUL IN PREVENTING HYPOXIC INJURY
EP2643470A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ILLNESSES AND SUFFERINGS RELATING TO D-DT
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
GB201119458D0 (en) Compositions for treatment of sleep disorders